Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04994535 · ClinicalTrials.gov registry record · Phase 3
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
A Phase 3 study of Platysma Prominence, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
- 20
- Study locations
NCT04994535 is a Phase 3 study of Platysma Prominence that has completed, run by AbbVie. The registered enrollment target is 426 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT04994535, a Phase 3 study of Platysma Prominence, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence. Study doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study across approximately 35 sites in USA, Belgium, Canada, Germany and the UK. Participants will receive a single treatment of intramuscular injection of onabotulinumtoxinA (BOTOX) or placebo on Day 1 during this 4 month long study. Participants will attend regular monthly visits during the study at the study site.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG OnabotulinumtoxinA
Study Locations (20)
Texas
- DermResearch, Inc. Austin, TX /ID# 249904 - Austin
- Bellaire Dermatology Associates /ID# 249902 - Bellaire
- Austin Institute for Clinical Research at SBA Dermatology /ID# 232104 - Houston
- Austin Institute for Clinical Research /ID# 244936 - Pflugerville
California
- Westside Aesthetics /ID# 231196 - Los Angeles
- Skin Care and Laser Physicians of Beverly Hills /ID# 231194 - Los Angeles
- Moradi MD /ID# 244719 - Vista
Florida
- Skin Research Institute LLC /ID# 231195 - Coral Gables
- Skin and Cancer Associates, LLP /ID# 231189 - Miami
Illinois
- DeNova Research /ID# 231191 - Chicago
- Oak Dermatology in Naperville /ID# 231193 - Naperville
Michigan
- BOYD Beauty Birmingham /ID# 231190 - Birmingham
- Michigan Center for Research Corporation /ID# 249911 - Clinton Township
New York
- The Center for Dermatology Cosmetics & Laser Surgery /ID# 231187 - Mount Kisco
- Luxurgery /ID# 244924 - New York
Alabama
- Total Skin and Beauty Derm Ctr /ID# 249905 - Birmingham
Louisiana
- Etre Cosmetic Dermatology and Laser Center /ID# 231192 - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2021-08-10 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04994535
The ClinicalTrials.gov registry entry for NCT04994535 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Platysma Prominence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04994535 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04994535 about?
NCT04994535 is a clinical study titled "A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence". The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence. Study doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant w...
What is the current status of trial NCT04994535?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2021-08-10. Estimated completion is 2023-06-14.
What conditions does trial NCT04994535 study?
This clinical trial studies the following conditions: Platysma Prominence.
What interventions are being tested in trial NCT04994535?
The interventions under investigation include: Placebo (DRUG), OnabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT04994535?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04994535 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platysma Prominence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.